NYSE: SOLV

Solventum (SOLV) Stock Analysis & Forecast

Nov 13 close

$89.08+0.27 (+0.3%)

Gekko Brief

AI summaryNov 9 close

Solventum's week centered on third-quarter results that beat expectations on organic growth and earnings, with adjusted EPS of $1.45 and organic growth of approximately 4%, prompting a third guidance raise for 2026. Revenue fell 7.0% and the company reported a net loss of $12 million on $1.949 billion in total net sales, which it attributed to the reversal of advance orders and an ERP cutover rather than underlying demand. The company also disclosed it has completed over 90% of its separation from 3M, including renegotiated raw material agreements, and confirmed plans to separate its Health Information Systems business to sharpen focus on MedSurg and Dental. BTIG raised its price target to $100 from $95 while maintaining a Buy rating following the results.

Shares closed at $90.43, up 0.1% on the day, sitting above both the 50-day average of $87.71 and the 200-day average of $78.61, with one-year return at 36.4%. The GekkoIndex reading sits at 50, placing the stock in the Neutral zone, though the index has declined 12.7 over the past five sessions. Price remains 16.8% below Gekko Fair Value of $108.68.

The next earnings date falls on 25 February 2027, outside a typical 20-trading-day hold. Over the last 30 days, one unusual options signal appeared, accompanied by put premium of $342,040 and no call premium. Analyst consensus across 8 firms shows 5 buy and 3 hold ratings, with a consensus target of $94.69.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Solventum price vs fair value

$107.31$89.08Nov ’25May ’26Nov ’26
Close $89.08200-day averageGekko Fair Value $107.31

Solventum quick facts

Market cap
$15.14B
P/E ratio
99.8
Forward P/E
12.8
EPS, TTM
$0.89
Revenue, TTM
$8.16B
Profit margin
1.9%
Dividend yield
—
Beta
0.75
Volume
917,953 avg 1.26M
1-year return
+20.7%
Typical daily move
±3.7%
Typical 20-day move
±5.4%
50-day average
$87.52
200-day average
$78.84
Next earnings
Feb 25 after close
Shares outstanding
170.0M
52-week range
$62.38$94.16

Solventum swing-trade checklist

Solventum scores 3 supportive, 1 mixed and 0 headwinds across the 4 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $89.08 is above the 50-day ($87.52) and 200-day ($78.84) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    54.5, Neutral

    Reading 54.5 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    17.0% below

    Price is 17% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityno data

    No data

    Not enough years of history for a seasonal read.

A description of current data, not a recommendation. How this page works

Solventum stock chart and price history

Solventum closed at $89.08 on Nov 13, 2026, +20.7% over the past year, inside a 52-week range of $62.38 to $94.16.

Close50-day average200-day averageVolume
Solventum share price, past year, with 50-day and 200-day moving averages and volume$70$80DecJan 2026FebMarAprMayJunJulAugSepOctNov89.08

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+1.4%
3 months
+2.6%
6 months
+20.0%
1 year
+20.7%
The full SOLV chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SOLV in Gekko

Follow Solventum through every session

Put SOLV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track SOLV in GekkoFree for 7 days. No credit card required.

About Solventum

Solventum works in healthcare, developing, making and selling a range of products and services aimed at meeting needs across the industry, from clinical settings to individual patients. It covers ground spanning surgical and wound care supplies through to dental products and digital health software, giving it a footprint across several distinct areas of medical and clinical support.

The company organizes its operations into four segments. Medsurg covers wound care products, I.V. site tools, sterilization systems, temperature management devices, surgical instruments, stethoscopes and electrodes. Dental Solutions supplies orthodontic and dental items including brackets, clear aligners, filling materials and bonding agents. Health Information Systems focuses on software such as physician documentation tools, billing and coding automation, classification systems, voice recognition and data visualization. Purification and Filtration provides filters, purifiers, cartridges and membranes used in purification processes.

Solventum was established in 2023 and is headquartered in Saint Paul, Minnesota. Its shares are listed on the NYSE under the ticker SOLV.

Listed
NYSE
Sector
Health services
Industry
Medical/Nursing services
Website
solventum.com

Solventum GekkoIndex: the smart money zone

Solventum’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.5, in the Neutral zone, up 4 points over five sessions.

010054.5Neutral

Up 4 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying41−0.7%−1.5%+2.1%+13.8%
Accumulation215+0.3%+0.1%+0.1%+3.3%
Neutral (current zone)348+0.4%+1.3%+2.0%+3.2%
Distribution48+0.3%−1.4%−0.5%−1.0%
Selling1Too few readings yet

Average SOLV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the SOLV price, zone by zone.Track SOLV in Gekko

Is Solventum stock overvalued? Gekko Fair Value

Solventum trades 17.0% below Gekko Fair Value of $107.31, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Solventum shares are worth, recalculated every trading day.

$107.31

Gekko Fair Value, Nov 14, 2026

17.0% Undervalued

At the end of Aug 2026 the price was 18.5% below the estimate.

Gekko Fair ValueShare price, month end
$107$89Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open SOLV in Gekko

Solventum insider and Congress trading

No open-market insider purchases were filed for Solventum, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for SOLV in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every SOLV insider filing, plotted on the chart in Gekko.Open SOLV in Gekko

Congress trades last 90 days

No trades in SOLV were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for SOLV, plotted on the chart in Gekko.Open SOLV in Gekko

Buybacks

Solventum has been buying back its own shares.

Latest authorization
$1.00B, Dec 16, 2025
Bought back, quarter ended Sep 30, 2026
$48.00M
As a share of market cap
0.32%

From company filings.

Hedge funds and billionaires quarter ended Sep 30

2of the funds Gekko tracks hold SOLV.

1added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Solventum earnings: next date and track record

Solventum reports on Feb 25, 2027, after the close (102 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±4.2%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−2.3%Nov ’24−5.1%Feb ’25+7.2%May ’25+1.1%Aug ’25+5.7%Nov ’25−1.2%Feb ’26+5.3%May ’26−5.7%Aug ’26

Last earnings call, Aug 5, 2026 AI summary

What they said
Solventum Q2 2026 results beat expectations on both top and bottom line, with organic growth and EPS ahead of plan and healthy performance across all segments. The company accelerated its $1 billion share repurchase program. A major strategic move was announced: separating the Health Information Systems (HIS) business to maximize shareholder value and sharpen focus on MedSurg and Dental. ERP cutover from 3M is in final stages.
Guidance
Management stated the company is on track to achieve its long-range plan earlier than expected. An Investor Day is planned for Q1 next year to outline the post-HIS long-range plan and RemainCo strategy. HIS separation is being pursued via a path to maximize value, either as independent company or merger.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026$2.55
est $1.90
+34.2%$2.21B
est $2.15B
+2.6%−5.7%
May 5, 2026$1.48
est $1.34
+10.4%$2.01B
est $1.97B
+2.0%+5.3%
Feb 26, 2026$1.57
est $1.50
+4.7%$2.00B
est $1.96B
+1.8%−1.2%
Nov 6, 2025$1.50
est $1.43
+4.9%$2.10B
est $2.06B
+2.0%+5.7%
Aug 7, 2025$1.69
est $1.45
+16.6%$2.16B
est $2.12B
+2.0%+1.1%
May 8, 2025$1.34
est $1.21
+10.7%$2.07B
est $2.02B
+2.7%+7.2%
Feb 27, 2025$1.41
est $1.50
−6.0%$2.07B
est $2.05B
+1.1%−5.1%
Nov 7, 2024$1.64
est $1.54
+6.5%$2.08B
est $2.06B
+1.2%−2.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Solventum stock forecast and analyst price targets

Analysts’ average 12-month price target for Solventum is $98.38, +10.4% from the last close, from 8 firms rating the stock in the last 90 days.

$98.38consensus 12-month target, +10.4% from the last close
Low $92High $115
Buy5
Hold3
Sell0

Each firm’s latest rating in the last 90 days: 8 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9UBSBuy, maintained$105+17.9%
Nov 6Mizuho SecuritiesBuy, maintained$115+29.1%
Nov 6BTIGBuy, reiterated$100+12.3%
Nov 6Wells FargoHold, reiterated$95+6.6%
Nov 6Piper SandlerBuy, reiterated$110+23.5%
+2.0%average 20-day move after past Neutral readings
±3.7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Solventum market cap and key statistics

Solventum’s market cap is $15.14B, with a P/E ratio of 99.8 and revenue of $8.16B over the last twelve months.

Valuation

Market cap
$15.14B
P/E ratio
99.8
Forward P/E
12.8
EPS, TTM
$0.89
Gekko Fair Value
$107.31

Trading

Volume
917,953
Avg volume, 20 days
1.26M
52-week high
$94.16
52-week low
$62.38
Shares outstanding
170.0M

Financials

Revenue, TTM
$8.16B
Profit margin
1.9%
Return on equity
3.2%
Quarterly earnings growth, YoY
+3.9%

Risk and income

Beta
0.75
Typical daily move
±3.7%
Typical 20-day move
±5.4%

Solventum stock news this week

Coverage of Solventum this week reads positive: 3 positive, 2 neutral and 2 negative headlines.

News sentiment positive

Solventum peers

Solventum’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LHLabcorp−1.0%Neutral8.5% above
GHGuardant Health−2.8%Accumulation16.4% below
BTSGBrightSpring Health Services0.0%Neutral11.0% above
EHCEncompass Health−0.4%Neutral14.7% above
ENSGEnsign+0.3%Neutral15.6% above
DVADaVita−0.3%Accumulation25.6% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical/Nursing services

Solventum stock FAQ

What is Solventum’s market cap?

Solventum’s market cap is $15.14B at the Nov 13, 2026 close of $89.08, with 170.0M shares outstanding. The shares trade on a P/E ratio of 99.8.

What is the Solventum stock forecast?

The consensus analyst 12-month price target for Solventum is $98.38, +10.4% from the last close. Of the 8 firms that rated the stock in the last 90 days, 5 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Solventum stock overvalued or undervalued?

On Gekko’s estimate Solventum is undervalued: the Nov 13, 2026 close of $89.08 is 17.0% below Gekko Fair Value of $107.31. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Solventum report earnings next?

Solventum is expected to report on Feb 25, 2027, after the market closes (102 days away). Analysts expect earnings of $1.77 per share on revenue of $2.09B. Solventum beat the earnings estimate in 7 of its last 8 reports, moving 4.2% on average across the report.

What is Solventum’s 52-week high and low?

Solventum’s 52-week high is $94.16 and its 52-week low is $62.38; it closed at $89.08 on Nov 13, 2026, +20.7% over the past year. Over the last five years the shares peaked at $96.05 on Mar 26, 2024.

Is Solventum stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 4 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Solventum the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.